<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="79062">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02079246</url>
  </required_header>
  <id_info>
    <org_study_id>14861B</org_study_id>
    <secondary_id>2013-000001-23</secondary_id>
    <nct_id>NCT02079246</nct_id>
  </id_info>
  <brief_title>Long-term Safety and Tolerability of Lu AE58054 as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease</brief_title>
  <acronym>STAR Extension</acronym>
  <official_title>An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Lu AE58054 as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive therapy to
      donepezil in patients with mild-moderate AD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Up to Week 32</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of withdrawals</measure>
    <time_frame>Up to Week 32</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cognition</measure>
    <time_frame>Baseline and Week 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in global impression</measure>
    <time_frame>Baseline and Week 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functioning</measure>
    <time_frame>Baseline and Week 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL23) total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in behavioural disturbance</measure>
    <time_frame>Baseline and Week 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Neuropsychiatric Inventory (NPI) total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive aspects of mental function</measure>
    <time_frame>Baseline and Week 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Mini Mental State Examination (MMSE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of Suicidality Using C-SSRS Scores</measure>
    <time_frame>Up to Week 28</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Columbia Suicide Severity Rating Scale (C-SSRS)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1770</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Lu AE58054 60 mg (or 30 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lu AE58054 adjunct to 10 mg Donepezil. The dose to be maintained throughout the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AE58054 60 mg (or 30 mg)</intervention_name>
    <description>once daily, encapsulated tablets, orally</description>
    <arm_group_label>Lu AE58054 60 mg (or 30 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has completed Visit 7 (Completion Visit) in the lead-in double-blind,
             placebo controlled clinical studies 14861A/NCT01955161 or 14862A/NCT02006641.

        Exclusion Criteria:

          -  The patient has a moderate or severe ongoing adverse event from the lead-in study
             considered a potential safety risk by the investigator.

          -  The patient has experienced seizures before Completion Visit in the lead-in study.

          -  The patient has evidence of clinically significant disease.

          -  The patient's donepezil treatment is likely to be interrupted or discontinued during
             the study.

          -  The patient is receiving therapy with another acetylcholinesterase inhibitors (AChEI)
             or memantine.

        Other protocol-defined inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <email>LundbeckClinicalTrials@lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>US018</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CZ001</name>
      <address>
        <city>Praha 2</city>
        <zip>120 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CZ002</name>
      <address>
        <city>Praha 6</city>
        <zip>160 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CZ005</name>
      <address>
        <city>Rychnov nad Kneznou</city>
        <zip>516 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>February 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
